Extension Study Evaluating The Safety And Tolerability of AMX0035
Status:
Not yet recruiting
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
The primary objective is to evaluate the safety and tolerability of AMX0035 over 108 weeks of
open label treatment for participants previously enrolled in Study A35-004 (PHOENIX).